For the twelve months ended Sep 30, 2026, Ardent Health Inc. reported $6.45B of revenue and $146.22M of net income.
ARDT revenue was $1.62B in fiscal Q3 2026 (ended Sep 30, 2026), up 3.1% from a year earlier and up 0.2% from the prior quarter. For the full fiscal 2025 it was $6.32B, up 6.0% from fiscal 2024. It rose in each of the last 3 fiscal years.
ARDT net income was $44.52M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$23.48M a year earlier and up 163.4% from the prior quarter. For the full fiscal 2025 it was $135.81M, down 35.4% from fiscal 2024. It rose in 1 of the last 3 fiscal years.
ARDT diluted EPS was $0.31 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.17 a year earlier and up 158.3% from the prior quarter. For the full fiscal 2025 it was $0.96, down 39.2% from fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $6.32B | $5.97B | $5.41B | $5.13B |
| Selling, general and admin | $140.80M | $132.40M | $114.60M | $75.30M |
| Pre-tax income | $286.36M | $363.06M | $151.61M | $311.48M |
| Income tax | $56.22M | $63.35M | $22.64M | $46.11M |
| Net income | $135.81M | $210.34M | $53.90M | $188.91M |
| EPS, basic | $0.96 | $1.59 | $0.43 | $1.50 |
| EPS, diluted | $0.96 | $1.58 | $0.43 | $1.50 |
| Diluted shares | 141.5M | 132.7M | 126.1M | 126.1M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $709.60M | $556.78M | $437.58M | $456.12M |
| Receivables | $686.10M | $743.03M | $775.45M | - |
| Inventory | $118.59M | $115.09M | $105.48M | - |
| Current assets | $2.06B | $1.83B | $1.62B | - |
| Goodwill | $879.45M | $852.08M | $844.70M | $844.70M |
| Total assets | $5.29B | $4.96B | $4.73B | - |
| Current liabilities | $1.05B | $945.42M | $994.10M | - |
| Short-term debt | $23.44M | $9.23M | $18.61M | - |
| Long-term debt | $1.08B | $1.09B | $1.17B | - |
| Total debt | $1.10B | $1.10B | $1.19B | - |
| Total liabilities | $3.61B | $3.43B | $3.65B | - |
| Shareholders' equity | $1.29B | $1.52B | $1.08B | $1.04B |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | $470.51M | $315.03M | $221.70M | -$38.36M |
| Investing cash flow | -$214.23M | -$220.46M | -$137.98M | $46.58M |
| Financing cash flow | -$103.47M | $24.64M | -$102.26M | -$270.33M |
| Dividends paid | - | $0 | $0 | $174.81M |
| Depreciation and amortization | $155.70M | $146.29M | $140.84M | $138.17M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | 6.0% | 10.3% | 5.5% | - |
| Net income growth, YoY | -35.4% | 290.2% | -71.5% | - |
| EPS growth, YoY | -39.2% | 267.4% | -71.3% | - |
| Net margin | 2.1% | 3.5% | 1.0% | 3.7% |
| Return on equity | 10.5% | 13.8% | 5.0% | 18.2% |
| Return on assets | 2.6% | 4.2% | 1.1% | - |
| Current ratio | 1.97 | 1.94 | 1.63 | - |
| Debt to equity | 0.85 | 0.72 | 1.10 | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.62B | $1.62B | $1.60B | $1.61B | $1.58B | $1.65B | $1.50B | $1.61B | $1.45B | $1.47B | $1.44B | $1.35B |
| Selling, general and admin | $42.40M | $61.20M | $48.60M | $36.80M | $36.50M | $32.60M | $34.90M | $36.70M | $33.70M | $29.10M | $32.90M | $32.40M |
| Pre-tax income | $81.03M | $43.20M | $74.59M | $92.37M | -$2.20M | $121.99M | $74.20M | $167.25M | $57.07M | $82.18M | $56.56M | $8.83M |
| Income tax | $17.64M | $8.51M | $16.10M | $18.11M | -$3.41M | $26.29M | $15.23M | $26.36M | $11.06M | $15.22M | $10.71M | -$1.95M |
| Net income | $44.52M | $16.90M | $39.85M | $44.96M | -$23.48M | $72.95M | $41.38M | $114.20M | $26.32M | $42.77M | $27.05M | -$4.15M |
| EPS, basic | $0.32 | $0.12 | $0.28 | $0.31 | -$0.17 | $0.52 | $0.30 | $0.85 | $0.19 | $0.34 | $0.21 | - |
| EPS, diluted | $0.31 | $0.12 | $0.28 | $0.32 | -$0.17 | $0.52 | $0.29 | $0.84 | $0.19 | $0.34 | $0.21 | - |
| Diluted shares | 141.7M | 143.1M | 141.8M | - | 141.2M | 141.5M | 140.7M | - | 137.5M | 126.1M | 126.1M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $766.24M | $724.48M | $609.69M | $709.60M | $609.44M | $540.63M | $495.04M | $556.78M | $563.14M | $334.54M | $372.77M | $437.58M |
| Receivables | $661.85M | $695.95M | $685.99M | $686.10M | $729.41M | $758.64M | $776.52M | $743.03M | $705.75M | $720.99M | - | $775.45M |
| Inventory | $110.10M | $116.02M | $119.84M | $118.59M | $121.59M | $118.40M | $120.36M | $115.09M | $108.23M | $105.01M | - | $105.48M |
| Current assets | $2.17B | $2.05B | $2.02B | $2.06B | $1.96B | $1.88B | $1.76B | $1.83B | $1.69B | $1.50B | - | $1.62B |
| Goodwill | $861.86M | $879.26M | $879.26M | $879.45M | $877.51M | $877.68M | $876.59M | $852.08M | $852.00M | $852.00M | - | $844.70M |
| Total assets | $5.35B | $5.28B | $5.25B | $5.29B | $5.15B | $5.03B | $4.91B | $4.96B | $4.80B | $4.61B | - | $4.73B |
| Current liabilities | $1.02B | $976.32M | $951.48M | $1.05B | $943.15M | $880.87M | $830.14M | $945.42M | $887.33M | $908.56M | - | $994.10M |
| Short-term debt | $28.76M | $28.57M | $37.63M | $23.44M | $19.34M | $19.33M | $17.76M | $9.23M | $12.17M | $10.72M | - | $18.61M |
| Long-term debt | $1.07B | $1.07B | $1.07B | $1.08B | $1.09B | $1.09B | $1.09B | $1.09B | $1.08B | $1.08B | - | $1.17B |
| Total debt | $1.10B | $1.10B | $1.11B | $1.10B | $1.11B | $1.11B | $1.11B | $1.10B | $1.10B | $1.09B | - | $1.19B |
| Total liabilities | $3.57B | $3.54B | $3.52B | $3.61B | $3.52B | $3.38B | $3.35B | $3.43B | $3.41B | $3.45B | - | $3.65B |
| Shareholders' equity | $1.40B | $1.75B | $1.73B | $1.29B | $1.63B | $1.65B | $1.56B | $1.52B | $1.38B | $1.16B | $1.11B | $1.08B |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $121.93M | $196.74M | -$60.22M | $223.44M | $154.37M | $117.49M | -$24.79M | $119.57M | $89.71M | $120.44M | -$14.69M | $67.50M |
| Investing cash flow | -$40.14M | -$39.18M | -$27.90M | -$86.23M | -$58.63M | -$46.25M | -$23.12M | -$105.44M | -$44.51M | -$38.87M | -$31.64M | -$56.71M |
| Financing cash flow | -$40.03M | -$42.77M | -$11.79M | -$37.05M | -$26.93M | -$25.66M | -$13.83M | -$20.48M | $183.41M | -$119.80M | -$18.48M | -$17.89M |
| Share repurchases | $10.98M | - | - | - | $0 | - | - | - | - | - | - | - |
| Depreciation and amortization | $41.06M | $41.34M | $42.99M | $41.04M | $39.16M | $39.31M | $36.20M | $37.85M | $36.77M | $36.31M | $35.35M | $35.98M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 3.1% | -1.4% | 7.0% | -0.1% | 8.8% | 11.9% | 4.0% | 19.3% | 5.2% | 7.5% | 9.3% | - |
| Net income growth, YoY | - | -76.8% | -3.7% | -60.6% | - | 70.6% | 53.0% | - | 26.3% | 29.3% | 552.8% | - |
| EPS growth, YoY | - | -76.9% | -3.4% | -61.9% | - | 52.9% | 38.1% | - | 11.8% | 30.8% | - | - |
| Net margin | 2.7% | 1.0% | 2.5% | 2.8% | -1.5% | 4.4% | 2.8% | 7.1% | 1.8% | 2.9% | 1.9% | -0.3% |
| Current ratio | 2.13 | 2.10 | 2.12 | 1.97 | 2.08 | 2.13 | 2.12 | 1.94 | 1.91 | 1.65 | - | 1.63 |
| Debt to equity | 0.79 | 0.63 | 0.64 | 0.85 | 0.68 | 0.67 | 0.71 | 0.72 | 0.79 | 0.94 | - | 1.10 |
Source: XBRL data Ardent Health Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ARDT | $6.45B | +2.0% | $146.22M | 2.3% | $2.53B |
| HCA | $78.70B | +5.8% | $6.78B | 8.6% | $105.47B |
| THC | $22.15B | +6.2% | $2.90B | 13.1% | $23.00B |
| EHC | $6.34B | +9.4% | $644.40M | 10.2% | $13.85B |
| UHS | $18.35B | +8.0% | $1.46B | 8.0% | $11.62B |
| ENSG | $5.67B | +17.5% | $399.12M | 7.0% | $10.62B |
| PACS | $5.71B | +11.0% | $277.58M | 4.9% | $7.74B |
| SGRY | $3.36B | +2.2% | -$87.00M | -2.6% | $3.46B |
| NHC | $1.58B | +5.6% | $115.13M | 7.3% | $3.29B |